More articles from 05.01 - Airway pharmacology and treatment

Utility of “smart” inhaler and suppression of fractional exhaled nitric oxide (FeNO): does it make a difference to patient outcomes?
Y Y See, E C Y Chow, M Crooks, M Robinson, K Watkins, F Turner, J Thompson, S Faruqi, E C Y Chow

European Respiratory Journal Sep 2022, 60 (suppl 66) 3865; DOI: 10.1183/13993003.congress-2022.3865
Using clusters of asthmatic patients to quantitatively estimate, prior to initiating treatment, the likelihood of β2-agonist response in asthma patients
E Delgado-Eckert, C Thamrin, I Town, D R Taylor, U Frey

European Respiratory Journal Sep 2022, 60 (suppl 66) 3699; DOI: 10.1183/13993003.congress-2022.3699
Effect of benralizumab on recurrent COPD exacerbations
D Singh, G J Criner, A Agusti, M Bafadhel, J Söderström, G Luporini Saraiva, Y Song, I Licaj, M Jison, U J Martin, I Psallidas

European Respiratory Journal Sep 2022, 60 (suppl 66) 3906; DOI: 10.1183/13993003.congress-2022.3906
Benralizumab attenuates blood and airway eosinophilia in severe asthmatics with inadequate response to anti-IL-5 neutralizing antibodies
M Mukherjee, A Bhalla, C Venegas-Garrido, C Huang, K Radford, M Kjarsgaard, S Lauks, K Son, N Lavigne, R Sehmi, P O'Byrne, P Nair

European Respiratory Journal Sep 2022, 60 (suppl 66) 3994; DOI: 10.1183/13993003.congress-2022.3994
The experience of dual biologic therapy in patients with eosinophilic asthma and autoimmune diseases
A M Matthaiou, N Bizymi, L Ettronier, E Bibaki, J Morel, N Tzanakis, A Bourdin, K Antoniou

European Respiratory Journal Sep 2022, 60 (suppl 66) 3744; DOI: 10.1183/13993003.congress-2022.3744
Compliance to pharmacological therapy of COPD patients with skeletal muscle dysfunction
V Poberezhets, A Demchuk, Y Mostovoy

European Respiratory Journal Sep 2022, 60 (suppl 66) 3992; DOI: 10.1183/13993003.congress-2022.3992
Economic impact of oral corticosteroids in severe asthmatics: a simulation study in selected European countries
A Bourdin, E H Bel, B Dahlén, R Djukanovic, E Heffler, P Kuna, R Louis, C Porsbjerg, D Ramos-Barbon, S Škrgat, G M Bruno, S Di Matteo, C Martinotti, G L Colombo, T Paulsson, B Mascialino

European Respiratory Journal Sep 2022, 60 (suppl 66) 3816; DOI: 10.1183/13993003.congress-2022.3816
Omalizumab-treated severe allergic asthmatics have comparable small airways function to healthy controls
H Kalsi, A Hakim, S Meah, P Paredi, M Biddiscombee, O Usmani

European Respiratory Journal Sep 2022, 60 (suppl 66) 4148; DOI: 10.1183/13993003.congress-2022.4148
Subcutaneous specific immunotherapy (SCIT) added to omalizumab in severe allergic asthma patients -efficacy and safety M.Christopoulou, J.Moisidis, L.Panteli and A.Christopoulos Asthma Clinics Private outpatient clinic Patras/Greece
A Christopoulos, M Christopoulou, L Panteli, I Moisidis, I Christopoulos

European Respiratory Journal Sep 2022, 60 (suppl 66) 3968; DOI: 10.1183/13993003.congress-2022.3968
Suppressive effect of corticosteroid treatment on urinary levels of androgens and cortisol in mild and severe asthma
V Yasinska, C Gómez, J Kolmert, A James, L I Andersson, B Dahlén, C E Wheelock, S Dahlén, E Wikström-Jonsson, ( On Behalf Of The U-Biopred Study Group)

European Respiratory Journal Sep 2022, 60 (suppl 66) 3889; DOI: 10.1183/13993003.congress-2022.3889

Main menu

User menu

Search

More articles from 05.01 - Airway pharmacology and treatment

Pages

Contact us